Title | Exploiting vita-PAMPs in vaccines. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | J Blander, M, Barbet, G |
Journal | Curr Opin Pharmacol |
Volume | 41 |
Pagination | 128-136 |
Date Published | 2018 Jun 08 |
ISSN | 1471-4973 |
Abstract | Live attenuated vaccines elicit stronger protective immunity than dead vaccines. Distinct PAMPs designated as vita-PAMPs signify microbial viability to innate immune cells. Two vita-PAMPs have been characterized: cyclic-di-adenosine-monophosphate (c-di-AMP) and prokaryotic messenger RNA (mRNA). c-di-AMP produced by live Gram-positive bacteria elicits augmented production of STING-dependent type-I interferon, whereas prokaryotic mRNA from live bacteria is detected by TLR8 enabling discrimination of live from dead bacteria. Bacterial mRNA from live Gram-negative bacteria triggers a heightened type-I interferon and NLRP3 inflammasome response. By mobilizing unique viability-associated innate responses, vita-PAMPs mobilize adaptive immunity that best elicits protection, including follicular T helper cell and antibody responses. Here, we review the molecular mechanisms that confer the unique adjuvanticity of vita-PAMPs and discuss their applications in vaccine design. |
DOI | 10.1016/j.coph.2018.05.012 |
Alternate Journal | Curr Opin Pharmacol |
PubMed ID | 29890457 |
Grant List | R01 DK111862 / DK / NIDDK NIH HHS / United States R01 AI127658 / AI / NIAID NIH HHS / United States R01 AI073899 / AI / NIAID NIH HHS / United States R01 AI095245 / AI / NIAID NIH HHS / United States R21 AI080959 / AI / NIAID NIH HHS / United States R01 AI123284 / AI / NIAID NIH HHS / United States |